Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising branded and generic pharmaceuticals.
We have a 40-year track record of innovation and success developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that continue to be marketed around the world.
Mayne Pharma offers a robust portfolio of branded and generic drugs in multiple therapeutic areas, including women's health and dermatology, and operates contract development and manufacturing organisations (CDMO) specialising in novel oral and topical dose forms.
